research 557 A peptide derivative with known anti-wrinkle properties was identified as potent dipeptiylpeptidase-4 inhibitor
A peptide known for reducing wrinkles also effectively inhibits an enzyme linked to skin inflammation and acne.
Search
for
Sort by
Research
390-420 / 1000+ results research Rational Design and Synthesis of 4-((1R,2R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a Novel, Nonsteroidal Androgen Receptor Antagonist Devoid of Phototoxicity for Dermatological Indications
PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
research Abstract 152
Six months of treatment improved PCOS symptoms and reduced AMH levels.
research Discovery and Optimization of Novel Pyridines as Highly Potent and Selective Glycogen Synthase Kinase 3 Inhibitors
New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.
research Minoxidil is a potential neuroprotective drug for paclitaxel-induced peripheral neuropathy
Minoxidil may protect nerves and improve hair quality during paclitaxel treatment.
research Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS)
The combined Myo-inositol and D-chiro-inositol treatment improved weight, hormone levels, and skin conditions in women with PCOS.
research The successful treatment of nephrogenic fibrosing dermopathy (NFD) with mycophenolate mofetil (MMF)
Mycophenolate mofetil improved skin condition in a man with nephrogenic fibrosing dermopathy.
research Risk of Autoimmune Skin Diseases Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis Using the FAERS Database
Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.
research Polycystic Ovary Syndrome
Certain medications can help treat PCOS symptoms, but they aren't FDA-approved for this use.
research PC-SPES Studies Promising, But Manufacturer Shuts Down
Promising cancer treatments were found, but the manufacturer closed.
research Management of Hirsutism
Antiandrogens, particularly flutamide and CPA, are most effective for treating hirsutism, with long-term use needed for best results.
research Inhibition of progesterone metabolism mimics the effect of progesterone withdrawal on forced swim test immobility
Blocking progesterone metabolism can cause depression-like behavior in mice.
research Metformin or thiazolidinedione therapy in PCOS?
Metformin and thiazolidinediones are similarly effective for PCOS, but metformin is often preferred due to fewer side effects.
research New Perspectives on Nutraceutical Insulin Sensitizing Agents in the Treatment of Psoriasis and Other Dermatological Diseases
Nutraceutical insulin-sensitizing agents may help treat skin conditions like psoriasis and acne.
research Supplementary Material for: A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS OF MEDICAL THERAPIES FOR LICHEN PLANOPILARIS.
Triple therapy with clobetasol, hydroxychloroquine, and N-acetylcysteine is recommended for better outcomes in treating lichen planopilaris.
research Anticonvulsant Activity of Progesterone and Neurosteroids in Progesterone Receptor Knockout Mice
Progesterone's seizure-reducing effects are mainly due to allopregnanolone, not progesterone receptors.
research Nano-PROTACs: state of the art and perspectives
Nano-PROTACs could improve drug targeting and delivery by using nanotechnology.
research Peroxisome proliferator-activated receptors-mediated diabetic wound healing regulates endothelial cells’ mitochondrial function via sonic hedgehog signaling
PPAR activation can improve diabetic wound healing by enhancing blood vessel function.
research Topiramate vs Divalproex Sodium in the Preventive Treatment of Migraine: A Prospective “Real‐World” Study
Both topiramate and divalproex sodium effectively reduce migraine frequency and are generally well-tolerated.
research Drug development to improve androgenetic alopecia on the Traditional Chinese Medicine theory
PMC shows promise as a treatment for hair loss.
research 494 Epidermolysis bullosa pruriginosa, muscular dystrophy, and immune-mediated myasthenia gravis in a patient with homozygous nonsense PLEC mutation
A patient with a PLEC mutation has epidermolysis bullosa, muscular dystrophy, and myasthenia gravis, which improved with steroid treatment.
research Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing
PCOS management includes lifestyle changes and medications, with ongoing research into repurposed drugs for better treatment options.
research Phospholipase A2 inhibition as potential therapy for inflammatory skin diseases
Inhibiting PLA2 enzymes may help treat inflammatory skin diseases like psoriasis and dermatitis.
research Integrating systemic agents in clinic-based practice
Systemic agents like cyclosporine, methotrexate, and acitretin help manage psoriasis but have significant side effects.
research ANTI‐ANDROGENS IN HIRSUTISM
Cyproterone acetate effectively treats hirsutism and related conditions.
research Cyproterone acetate and risk of meningioma: a nationwide cohort study
Taking high doses of Cyproterone acetate significantly increases the risk of meningioma in females.
research Experimental Evaluation of 3-meta-Pyridine-1,2,4-Oxadiazole Derivative of Deoxycholic Acid as a Prototype of 5-α-Reductase Inhibitors in In Silico and In Vivo Models
The new compound may be a safer alternative to finasteride for prostate protection.
research Modern Polycystic Ovary Syndrome (PCOS) Management: Intelligent Drug Delivery and Metabolic Reprogramming for Ovarian Restoration and Fertility Optimization
New treatments for PCOS using smart drug delivery, metabolic changes, and AI show promise but need more research.
research INTERFERONS IN DERMATOLOGY
Interferons are effective for some skin conditions and cancers, but can have side effects and need more research for optimal use.
research Urological Drug Price Stewardship: Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model
Adopting the Mark Cuban Cost Plus Drug Company pricing model could save Medicare about $1.29 billion on urological drugs.